Progesterone_NN receptors_NNS -_: animal_JJ models_NNS and_CC cell_NN signaling_VBG in_IN breast_NN cancer_NN :_: Role_NN of_IN steroid_NN receptor_NN coactivators_NNS and_CC corepressors_NNS of_IN progesterone_NN receptors_NNS in_IN breast_NN cancer_NN Abstract_NP |_SYM Progesterone_NP ,_, an_DT ovarian_JJ steroid_NN hormone_NN ,_, plays_VBZ a_DT key_JJ role_NN in_IN the_DT development_NN and_CC function_NN of_IN the_DT mammary_JJ gland_NN ,_, as_IN it_PP also_RB does_VBZ in_IN the_DT uterus_NN and_CC the_DT ovary_NN ._SENT The_DT action_NN of_IN progesterone_NN is_VBZ mediated_VBN through_IN its_PP$ intracellular_JJ cognate_JJ receptor_NN ,_, the_DT progesterone_NN receptor_NN (_( PR_NP )_) ,_, which_WDT functions_VBZ as_IN a_DT transcription_NN factor_NN that_WDT regulates_VBZ gene_NN expression_NN ._SENT As_RB with_IN other_JJ nuclear_JJ receptors_NNS ,_, coregulators_NNS (_( coactivators_NNS and_CC corepressors_NNS )_) recruited_VBN by_IN the_DT liganded_JJ or_CC unliganded_JJ PR_NP ,_, either_CC to_TO enhance_VB or_CC to_TO suppress_VB transcription_NN activity_NN ,_, modulate_VBP the_DT function_NN of_IN the_DT PR_NP ._SENT Mutation_NN or_CC aberrant_JJ expression_NN of_IN the_DT coregulators_NNS might_MD thus_RB affect_VB the_DT normal_JJ function_NN of_IN the_DT PR_NP and_CC hence_RB disrupt_VB the_DT normal_JJ development_NN of_IN the_DT mammary_JJ gland_NN ,_, which_WDT may_MD lead_VB to_TO breast_VB cancer_NN ._SENT breast_NN cancer_NN ,_, coactivator_NN ,_, corepressor_NN ,_, progesterone_NN receptor_NN ,_, The_DT progesterone_NN receptor_NN (_( PR_NP )_) is_VBZ a_DT member_NN of_IN the_DT nuclear_JJ receptor_NN superfamily_NN ,_, which_WDT specifically_RB regulates_VBZ the_DT expression_NN of_IN target_NN genes_NNS in_IN response_NN to_TO the_DT hormonal_JJ stimulus_NN ._SENT In_IN the_DT absence_NN of_IN progesterone_NN ,_, the_DT PR_NP is_VBZ sequestered_VBN in_IN a_DT nonproductive_JJ form_NN associated_VBN with_IN heat_NN shock_NN proteins_NNS and_CC other_JJ cellular_JJ chaperones_NNS ._SENT In_IN this_DT state_NN ,_, the_DT PR_NP is_VBZ considered_VBN unable_JJ to_TO influence_VB the_DT rate_NN of_IN transcription_NN of_IN its_PP$ cognate_JJ promoters_NNS ._SENT On_IN binding_VBG with_IN progesterone_NN ,_, the_DT PR_NP undergoes_VBZ a_DT series_NN of_IN events_NNS ,_, including_VBG conformational_JJ changes_NNS ,_, dissociation_NN from_IN heat_NN shock_NN protein_NN complexes_NNS ,_, dimerization_NN ,_, phosphorylation_NN ,_, and_CC nuclear_JJ translocation_NN ,_, which_WDT enables_VBZ its_PP$ binding_NN to_TO progesterone-response_NN elements_NNS within_IN the_DT regulatory_JJ regions_NNS of_IN target_NN genes_NNS ._SENT The_DT binding_NN of_IN PR_NP to_TO the_DT progesterone-response_NN elements_NNS is_VBZ followed_VBN by_IN the_DT recruitment_NN of_IN coactivators_NNS and_CC the_DT basal_JJ transcription_NN machinery_NN ,_, leading_VBG to_TO the_DT upregulation_NN of_IN target_NN gene_NN transcription_NN ._SENT The_DT PR_NP exists_VBZ as_RB two_CD isoforms_NNS in_IN most_JJS rodents_NNS and_CC humans_NNS ,_, PR-A_NP and_CC PR-B_NP ,_, which_WDT are_VBP produced_VBN from_IN a_DT single_JJ gene_NN by_IN translation_NN initiation_NN at_IN two_CD distinct_JJ start_NN codons_NNS under_IN the_DT control_NN of_IN separate_JJ promoters_NNS ._SENT The_DT difference_NN between_IN PR-A_NP and_CC PR-B_NP is_VBZ that_IN PR-A_NP is_VBZ a_DT truncated_JJ form_NN of_IN PR-B_NP ._SENT In_IN humans_NNS ,_, the_DT N-terminal_JJ 164_CD amino_NN acids_NNS of_IN PR-B_NN are_VBP missing_VBG in_IN isoform_NN PR-A_NP ._SENT Detailed_JJ molecular_JJ dissection_NN has_VBZ identified_VBN two_CD distinct_JJ activation_NN function_NN domains_NNS (_( AFs_NP )_) within_IN both_DT PRs_NN :_: AF-1_NP ,_, which_WDT is_VBZ located_VBN in_IN the_DT N-terminal_JJ region_NN ,_, is_VBZ ligand_NN independent_JJ ;_: AF-2_NP ,_, which_WDT is_VBZ ligand_NN dependent_JJ ,_, is_VBZ contained_VBN in_IN the_DT ligand-binding_NN domain_NN that_WDT is_VBZ located_VBN in_IN the_DT C-terminal_JJ region_NN ._SENT A_DT DNA-binding_NP domain_NN and_CC the_DT hinge_NN region_NN are_VBP mapped_VBN to_TO the_DT central_JJ region_NN of_IN both_DT receptors_NNS ._SENT Furthermore_RB ,_, a_DT unique_JJ activation_NN function_NN domain_NN ,_, AF-3_NP ,_, is_VBZ contained_VBN in_IN the_DT upstream_JJ segment_NN of_IN PR-B_NN that_WDT is_VBZ missing_VBG in_IN PR-A_NP ._SENT Figure_NP 1_CD |_SYM Schematic_JJ representation_NN of_IN the_DT progesterone_NN receptor_NN PR-A_NP and_CC PR-B_NP proteins_NNS ._SENT Schematic_JJ representation_NN of_IN the_DT progesterone_NN receptor_NN PR-A_NP and_CC PR-B_NP proteins_NNS ._SENT The_DT DNA-binding_NP domain_NN (_( DBD_NP )_) ,_, the_DT ligand-binding_NN domain_NN (_( LBD_NP )_) and_CC activation_NN function_NN domains_NNS (_( AFs_NP )_) are_VBP indicated_VBN ._SENT Progesterone_NN and_CC estrogen_NN are_VBP essential_JJ regulators_NNS of_IN female_JJ reproductive_JJ activity_NN ._SENT Through_IN their_PP$ cognate_JJ receptors_NNS ,_, estrogen_NN and_CC progesterone_NN regulate_VB the_DT normal_JJ development_NN of_IN the_DT ovary_NN ,_, the_DT uterus_NN and_CC the_DT mammary_JJ gland_NN ,_, and_CC play_VB key_JJ roles_NNS in_IN the_DT tumorigenesis_NN of_IN these_DT tissues_NNS ._SENT It_PP has_VBZ been_VBN demonstrated_VBN by_IN estrogen_NN receptor_NN (_( ER_NN )_) and_CC PR_NP knockout_NN mice_NNS that_IN estrogen_NN controls_VBZ the_DT early_JJ ductal_JJ morphogenesis_NN of_IN the_DT mammary_JJ gland_NN ,_, whereas_IN progesterone_NN controls_VBZ ductal_JJ branching_NN and_CC alveolar_JJ development_NN of_IN the_DT mammary_JJ gland_NN during_IN pregnancy_NN ._SENT Although_IN the_DT two_CD forms_NNS of_IN the_DT PR_NP have_VBP similar_JJ structures_NNS and_CC are_VBP identical_JJ in_IN DNA_NN and_CC ligand_NN binding_NN ,_, in_IN vitro_NN studies_NNS using_VBG a_DT reconstituted_VBN progesterone-responsive_JJ transcription_NN system_NN in_IN mammalian_JJ cells_NNS revealed_VBD that_IN PR-A_NP and_CC PR-B_NP are_VBP not_RB functionally_RB identical_JJ ._SENT In_IN most_JJS cases_NNS ,_, PR-B_NN acts_NNS as_IN a_DT potent_JJ activator_NN of_IN transcription_NN of_IN target_NN genes_NNS ,_, whereas_IN PR-A_NP acts_NNS as_IN a_DT dominant_JJ repressor_NN of_IN transcription_NN of_IN PR-B_NN as_RB well_RB as_IN a_DT few_JJ other_JJ nuclear_JJ receptors_NNS ._SENT The_DT AF-3_NP domain_NN in_IN PR-B_NN is_VBZ partially_RB responsible_JJ for_IN the_DT higher_JJR transcriptional_JJ activity_NN of_IN PR-B_NN relative_JJ to_TO PR-A_NP ._SENT Moreover_RB ,_, an_DT inhibitory_JJ function_NN domain_NN that_WDT is_VBZ located_VBN in_IN the_DT N-terminus_NP of_IN both_DT receptor_NN isoforms_NNS has_VBZ been_VBN identified_VBN ._SENT This_DT inhibition_NN function_NN domain_NN can_MD inhibit_VB the_DT activity_NN of_IN AF-1_NP and_CC AF-2_NP but_CC not_RB that_IN of_IN AF-3_NP ,_, which_WDT explains_VBZ why_WRB PR-B_NP is_VBZ a_DT potent_JJ activator_NN of_IN transcription_NN ._SENT The_DT inhibition_NN function_NN domain_NN is_VBZ functionally_RB independent_JJ and_CC is_VBZ transferable_JJ ;_: when_WRB placed_VBN upstream_RB of_IN the_DT ER_NN ,_, the_DT inhibition_NN function_NN domain_NN can_MD also_RB suppress_VB ER_JJ activity_NN ._SENT The_DT relative_JJ expression_NN of_IN PR-A_NP and_CC PR-B_NP in_IN the_DT target_NN tissues_NNS is_VBZ dependent_JJ on_IN species_NNS ,_, cellular_JJ context_NN ,_, and_CC the_DT physiological_JJ and_CC hormonal_JJ status_NN ._SENT The_DT ratio_NN of_IN PR-A_NP to_TO PR-B_NN in_IN specific_JJ tissues_NNS or_CC cell_NN types_NNS defines_VBZ the_DT physiological_JJ and_CC pharmacological_JJ responses_NNS to_TO progesterone_NN ._SENT In_IN the_DT mammary_JJ gland_NN ,_, the_DT ratios_NNS of_IN PR-A_NP to_TO PR-B_NP are_VBP constant_JJ from_IN puberty_NN to_TO pregnancy_NN ,_, although_IN there_EX are_VBP species_NN differences_NNS ._SENT From_IN PR-A_NP knockout_NN mice_NNS ,_, it_PP has_VBZ been_VBN demonstrated_VBN that_IN PR-B_NP is_VBZ mainly_RB responsible_JJ for_IN the_DT normal_JJ proliferative_JJ and_CC differentiative_JJ responses_NNS of_IN the_DT mammary_JJ gland_NN to_TO progesterone_NN ,_, because_IN PR-A_NP knockout_NN mice_NNS exhibit_VBP a_DT similar_JJ phenotype_NN to_TO PR_NP knockout_NN mice_NNS ._SENT Overexpression_NN of_IN PR-A_NP over_IN PR-B_NN in_IN transgenic_JJ mice_NNS results_NNS in_IN extensive_JJ epithelial_JJ cell_NN hyperplasia_NN ,_, in_IN excessive_JJ ductal_JJ branching_NN ,_, and_CC in_IN a_DT disorganized_VBN basement_NN membrane_NN ._SENT All_PDT these_DT features_NNS are_VBP associated_VBN with_IN neoplasia_NN ._SENT Furthermore_RB ,_, the_DT development_NN of_IN the_DT mammary_JJ gland_NN in_IN PR-B_NP overexpressed_VBD transgenic_JJ mice_NNS is_VBZ also_RB abnormal_JJ ,_, indicating_VBG that_IN a_DT regulated_JJ expression_NN of_IN PR-A_NP and_CC PR-B_NP and_CC the_DT native_JJ ratios_NNS of_IN the_DT two_CD isoforms_NNS are_VBP critical_JJ to_TO the_DT appropriate_JJ responsiveness_NN of_IN the_DT mammary_JJ gland_NN to_TO progesterone_NN ._SENT Consistent_JJ with_IN the_DT findings_NNS from_IN animal_JJ studies_NNS ,_, very_RB low_JJ levels_NNS of_IN PR-B_NN and_CC a_DT consequently_RB high_JJ PR-A:PR-B_NN ratio_NN were_VBD found_VBN in_IN a_DT significant_JJ proportion_NN of_IN human_JJ breast_NN cancer_NN samples_NNS ._SENT Taking_VBG these_DT findings_NNS together_RB ,_, it_PP can_MD be_VB inferred_VBN that_DT imbalance_NN of_IN PR-A_NP versus_CC PR-B_NP may_MD be_VB associated_VBN with_IN the_DT development_NN ,_, progression_NN or_CC prognosis_NN of_IN breast_NN cancer_NN ._SENT Coactivators_NNS are_VBP factors_NNS that_WDT can_MD interact_VB with_IN nuclear_JJ receptors_NNS in_IN a_DT ligand-dependent_JJ manner_NN and_CC enhance_VB their_PP$ transcriptional_JJ activity_NN ._SENT Corepressors_NNS are_VBP factors_NNS that_WDT interact_VBP with_IN nuclear_JJ receptors_NNS and_CC repress_VB their_PP$ transcriptional_JJ activity_NN ._SENT Both_DT types_NNS of_IN coregulators_NNS are_VBP required_VBN for_IN efficient_JJ modulation_NN of_IN target_NN gene_NN transcription_NN by_IN the_DT PR_NP ._SENT Changes_NNS in_IN the_DT expression_NN level_NN and_CC pattern_NN of_IN PR_NP coactivators_NNS or_CC corepressors_NNS ,_, or_CC mutation_NN of_IN their_PP$ function_NN domains_NNS ,_, might_MD therefore_RB affect_VB the_DT transcriptional_JJ activity_NN of_IN the_DT PR_NP and_CC hence_RB cause_VB disorders_NNS of_IN its_PP$ target_NN tissues_NNS ,_, including_VBG the_DT mammary_JJ gland_NN ._SENT The_DT present_JJ review_NN will_MD describe_VB the_DT coactivators_NNS and_CC corepressors_NNS that_WDT are_VBP involved_VBN in_IN the_DT transcriptional_JJ modulation_NN of_IN PRs_NN ,_, with_IN emphasis_NN on_IN their_PP$ roles_NNS in_IN breast_NN cancer_NN development_NN and_CC progression_NN ._SENT The_DT steroid_NN receptor_NN coactivator_NN family_NN |_SYM The_DT steroid_NN receptor_NN coactivator_NN (_( SRC_NP )_) family_NN is_VBZ composed_VBN of_IN three_CD distinct_JJ but_CC structurally_RB and_CC functionally_RB related_VBN members_NNS :_: SRC-1_NP (_( nuclear_JJ receptor_NN coactivator_NN 1_CD )_) ,_, SRC-2_NP (_( transcription_NN intermediary_NN factor_NN 2/glucocorticoid_JJ receptor-interacting_NN protein_NN 1/nuclear_JJ receptor_NN coactivator_NN 2_CD )_) ,_, and_CC SRC-3_NP (_( p300/CREB-binding_JJ protein_NN [_SYM CBP_NP ]_SYM cointegrator-associated_JJ protein/receptor-associated_JJ coactivator_NN 3/activator_NN of_IN thyroid_NN and_CC retinoid_NN receptors/amplified_NN in_IN breast_NN cancer_NN 1/thyroid_JJ receptor_NN activator_NN molecule_NN 1_CD )_) ._SENT SRC-1_NP was_VBD the_DT first_JJ identified_VBN coactivator_NN for_IN the_DT steroid_NN receptor_NN superfamily_NN ,_, which_WDT was_VBD cloned_VBN and_CC characterized_VBN in_IN 1995_CD ._SENT SRC-2_NP and_CC SRC-3_NP were_VBD then_RB identified_VBN thereafter_RB by_IN several_JJ laboratories_NNS ._SENT Sequence_NN analysis_NN of_IN SRC_NP proteins_NNS identified_VBD a_DT basic_JJ helix_NN --_: loop_NN --_: helix_NN domain_NN and_CC two_CD Per_NP --_: Arnt_NP --_: Sim_NP domains_NNS in_IN the_DT amino-terminal_JJ region_NN ._SENT The_DT basic_JJ helix_NN --_: loop_NN --_: helix/Per_NN --_: Arnt_NP --_: Sim_NP domain_NN is_VBZ highly_RB conserved_VBN among_IN the_DT SRC_NP members_NNS ,_, and_CC it_PP serves_VBZ as_IN a_DT DNA_NP binding_NN and_CC protein_NN dimerization_NN motif_NN in_IN many_JJ transcription_NN factors_NNS ._SENT Following_VBG the_DT basic_JJ helix_NN --_: loop_NN --_: helix/Per_NN --_: Arnt_NP --_: Sim_NP domain_NN ,_, there_EX are_VBP a_DT centrally_RB located_VBN receptor-interacting_NN domain_NN and_CC a_DT C-terminal_JJ transcriptional_JJ activation_NN domain_NN ._SENT Detailed_JJ analysis_NN revealed_VBD three_CD conserved_VBN LXXLL_NP motifs_NNS (_( nuclear_JJ receptor_NN box_NN )_) in_IN the_DT receptor-interacting_NN domain_NN ,_, which_WDT appear_VBP to_TO contribute_VB to_TO the_DT specificity_NN of_IN coactivator_NN --_: receptor_NN interaction_NN ._SENT Histone_NN acetyltransferase_NN activity_NN was_VBD identified_VBN in_IN the_DT C-terminal_JJ region_NN of_IN SRC_NP members_NNS ,_, and_CC there_RB also_RB exist_VB activation_NN domains_NNS that_WDT can_MD interact_VB with_IN the_DT CBP_NP ._SENT All_DT three_CD members_NNS of_IN the_DT SRC_NP family_NN interact_VBP with_IN the_DT PR_NP and_CC enhance_VB its_PP$ transcriptional_JJ activation_NN in_IN a_DT ligand-dependent_JJ manner_NN ._SENT Targeted_JJ deletion_NN of_IN the_DT SRC-1_JJ gene_NN in_IN mice_NNS has_VBZ indicated_VBN that_IN SRC-1_NP is_VBZ important_JJ for_IN the_DT biological_JJ actions_NNS of_IN progesterone_NN in_IN mammary_JJ gland_NN development_NN since_IN the_DT hormone-induced_JJ ductal_JJ elongation_NN and_CC alveolar_JJ development_NN is_VBZ greatly_RB impaired_VBN in_IN the_DT null_JJ mice_NNS ._SENT In_IN the_DT meantime_NN ,_, the_DT expression_NN of_IN SRC-2_NP mRNA_NP was_VBD elevated_VBN in_IN SRC-1_JJ null_JJ mice_NNS ,_, suggesting_VBG that_IN SRC-2_NP can_MD partially_RB compensate_VB for_IN SRC-1_JJ function_NN ._SENT SRC-3_NP is_VBZ the_DT most_RBS distinct_JJ among_IN the_DT three_CD members_NNS ._SENT It_PP coactivates_VBZ not_RB only_RB the_DT nuclear_JJ receptors_NNS ,_, but_CC also_RB other_JJ unrelated_JJ transcription_NN factors_NNS such_JJ as_IN those_DT in_IN the_DT cAMP_NN or_CC cytokine_NN pathways_NNS ._SENT Compared_VBN with_IN the_DT widespread_JJ expression_NN of_IN SRC-1_NP and_CC SRC-2_NP ,_, expression_NN of_IN SRC-3_NP is_VBZ restricted_VBN to_TO the_DT mammary_JJ gland_NN and_CC several_JJ other_JJ tissues_NNS ._SENT Disruption_NN of_IN the_DT SRC-3_NP gene_NN in_IN mice_NNS causes_VBZ severe_JJ growth_NN and_CC reproductive_JJ defects_NNS ,_, including_VBG the_DT retardation_NN of_IN mammary_JJ gland_NN development_NN ._SENT Furthermore_RB ,_, amplification_NN and_CC overexpression_NN of_IN SRC-3_NP were_VBD observed_VBN in_IN 10_CD %_NN and_CC 64_CD %_NN of_IN human_JJ primary_JJ breast_NN cancers_NNS ,_, respectively_RB ._SENT This_DT observation_NN indicates_VBZ that_IN SRC-3_NP is_VBZ not_RB only_RB essential_JJ for_IN the_DT normal_JJ mammary_JJ development_NN ,_, but_CC also_RB plays_VBZ a_DT role_NN in_IN breast_NN tumorigenesis_NN ._SENT E6-associated_JJ protein/RPF1_NN |_SYM E6-associated_JJ protein_NN (_( E6-AP_NP )_) and_CC RPF1_NP ,_, the_DT human_JJ homolog_NN of_IN yeast_NN RSP5_NP ,_, are_VBP E3_NP ubiquitin-protein_NN ligases_NNS that_WDT target_VBP proteins_NNS for_IN degradation_NN by_IN the_DT ubiquitin_NN pathway_NN ._SENT They_PP are_VBP also_RB characterized_VBN as_IN coactivators_NNS of_IN steroid_NN receptors_NNS ._SENT It_PP has_VBZ been_VBN demonstrated_VBN by_IN transient_JJ transfection_NN assay_NN that_IN RPF1_NP and_CC E6-AP_NP could_MD potentiate_VB the_DT ligand-dependent_JJ transcriptional_JJ activity_NN of_IN the_DT PR_NP ,_, the_DT glucocorticoid_JJ receptor_NN ,_, and_CC other_JJ nuclear_JJ receptors_NNS ._SENT Furthermore_RB ,_, RPF1_NP and_CC E6-AP_NP acted_VBD synergistically_RB to_TO enhance_VB PR_NP transactivation_NN ._SENT Additionally_RB ,_, the_DT coactivation_NN functions_NNS of_IN E6-AP_NP and_CC RPF1_NP are_VBP separable_JJ from_IN the_DT E3_NP ubiquitin-protein_NN ligase_NN activity_NN ,_, as_IN ubiquitin_NN ligase-defective_JJ E6-AP_NP and_CC RPF1_NP exhibited_VBD normal_JJ coactivation_NN function_NN ._SENT E6-AP_NP is_VBZ expressed_VBN in_IN many_JJ tissues_NNS ,_, including_VBG the_DT mammary_JJ gland_NN ._SENT From_IN its_PP$ ability_NN to_TO coactivate_VB the_DT PR_NP and_CC the_DT ER_NN in_IN a_DT hormone-dependent_JJ manner_NN ,_, it_PP was_VBD assumed_VBN that_IN E6-AP_NP is_VBZ an_DT essential_JJ regulator_NN for_IN the_DT development_NN of_IN normal_JJ mammary_JJ gland_NN and_CC mammary_JJ tumors_NNS ._SENT The_DT first_JJ evidence_NN of_IN a_DT relationship_NN between_IN E6-AP_NN and_CC breast_NN cancers_NNS was_VBD obtained_VBN from_IN the_DT study_NN of_IN a_DT spontaneous_JJ mouse_NN mammary_JJ tumorigenesis_NN model_NN ,_, which_WDT demonstrated_VBD that_IN E6-AP_NP was_VBD overexpressed_VBN in_IN tumors_NNS when_WRB compared_VBN with_IN normal_JJ tissues_NNS ._SENT We_PP recently_RB examined_VBD the_DT expression_NN pattern_NN of_IN E6-AP_NP in_IN biopsy_NN samples_NNS of_IN human_JJ breast_NN cancers_NNS ,_, and_CC our_PP$ results_NNS showed_VBD that_IN E6-AP_NP expression_NN was_VBD decreased_VBN in_IN tumors_NNS in_IN comparison_NN with_IN the_DT adjacent_JJ normal_JJ tissues_NNS (_( Gao_NP et_FW al._FW ,_, unpublished_JJ data_NNS ,_, 2002_CD )_) ._SENT Furthermore_RB ,_, we_PP demonstrated_VBD that_IN the_DT decreased_VBN expression_NN of_IN E6-AP_NP was_VBD stage_NN dependent_JJ ,_, and_CC that_IN the_DT expression_NN of_IN E6-AP_NP was_VBD inversely_RB correlated_VBN with_IN that_DT of_IN the_DT ER_NN in_IN breast_NN tumors_NNS ._SENT Since_IN the_DT ER_NN plays_VBZ a_DT major_JJ role_NN in_IN breast_NN cancer_NN development_NN and_CC the_DT PR_NP is_VBZ a_DT target_NN of_IN estrogen_NN ,_, the_DT changes_NNS of_IN the_DT expression_NN level_NN of_IN E6-AP_NP might_MD interfere_VB with_IN the_DT normal_JJ functioning_NN of_IN the_DT ER_NN and_CC the_DT PR_NP ._SENT Hence_RB ,_, E6-AP_NP may_MD participate_VB in_IN the_DT formation_NN and_CC progression_NN of_IN breast_NN tumors_NNS ._SENT Steroid_NN receptor_NN RNA_NP activator_NN |_SYM The_DT growing_VBG family_NN of_IN nuclear_JJ receptor_NN coactivators_NNS has_VBZ recently_RB acquired_VBN a_DT unique_JJ member_NN ,_, steroid_NN receptor_NN RNA_NP activator_NN (_( SRA_NP )_) ._SENT Differing_VBG from_IN the_DT other_JJ coactivators_NNS ,_, SRA_NP functions_NNS as_IN a_DT RNA_NP transcript_NN instead_RB of_IN as_IN a_DT protein_NN ._SENT SRA_NP specifically_RB coactivates_VBZ the_DT transcriptional_JJ activity_NN of_IN steroid_NN receptors_NNS ,_, including_VBG the_DT PR_NP ,_, the_DT ER_NN ,_, the_DT glucocorticoid_JJ receptor_NN ,_, and_CC the_DT androgen_NN receptor_NN ._SENT It_PP has_VBZ been_VBN demonstrated_VBN that_IN SRA_NP exists_VBZ in_IN a_DT ribonucleoprotein_NN complex_NN containing_VBG SRC-1_NP and_CC that_IN it_PP mediates_VBZ transactivation_NN through_IN the_DT AF-1_JJ domain_NN located_VBN at_IN the_DT N-terminal_JJ region_NN of_IN nuclear_JJ receptors_NNS ,_, distinguishing_VBG it_PP from_IN the_DT other_JJ coactivators_NNS ._SENT SRA_NP is_VBZ expressed_VBN in_IN normal_JJ and_CC malignant_JJ human_JJ mammary_JJ tissues_NNS ._SENT An_DT elevated_JJ expression_NN of_IN SRA_NP was_VBD found_VBN in_IN tumors_NNS compared_VBN with_IN the_DT adjacent_JJ normal_JJ region_NN ._SENT Although_IN it_PP is_VBZ currently_RB unknown_JJ whether_IN the_DT expression_NN of_IN SRA_NP is_VBZ correlated_VBN with_IN that_DT of_IN the_DT PR_NP or_CC the_DT ER_NN ,_, the_DT increase_NN in_IN the_DT SRA_NP levels_NNS in_IN tumor_NN cells_NNS may_MD contribute_VB to_TO the_DT altered_JJ ER/PR_NP action_NN that_WDT is_VBZ known_VBN to_TO occur_VB during_IN breast_NN tumorigenesis_NN ._SENT L7/SPA_NN |_SYM L7/SPA_NP is_VBZ a_DT 27_CD kDa_NN protein_NN containing_VBG a_DT basic_JJ leucine_NN zipper_NN domain_NN ._SENT L7/SPA_NP is_VBZ an_DT antagonist-specific_JJ transcriptional_JJ coactivator_NN because_IN it_PP can_MD only_RB potentiate_VB the_DT partial_JJ agonist_NN activity_NN of_IN some_DT antagonists_NNS ,_, including_VBG tamoxifen_NP and_CC RU486_NP ,_, but_CC has_VBZ no_DT effect_NN on_IN the_DT agonist-mediated_JJ transcription_NN ._SENT This_DT unique_JJ property_NN of_IN L7/SPA_NP suggests_VBZ that_IN it_PP might_MD play_VB a_DT role_NN in_IN the_DT development_NN of_IN resistance_NN to_TO hormone_NN therapy_NN for_IN breast_NN cancers_NNS ._SENT CBP/p300_NN |_SYM CBP_NP was_VBD initially_RB characterized_VBN as_IN a_DT coactivator_NN required_VBN for_IN efficient_JJ transactivation_NN of_IN cAMP-response_JJ element-binding_NN protein_NN ,_, and_CC p300_NN was_VBD first_RB identified_VBN as_IN a_DT coactivator_NN of_IN the_DT adenovirus_NN E1A_NP oncoprotein_NP ._SENT CBP_NP and_CC p300_JJ share_NN many_JJ functional_JJ properties_NNS :_: both_CC of_IN them_PP function_VBP as_IN coactivators_NNS for_IN multiple_JJ nuclear_JJ receptors_NNS as_RB well_RB as_IN p53_NN and_CC nuclear_JJ factor-kappaB_NN ,_, both_CC possess_VB intrinsic_JJ histone_NN acetyltransferase_NN activity_NN ,_, and_CC both_DT can_MD recruit_VB histone_NN acetyltransferase_NN and_CC CBP/p300-associated_JJ factor_NN ._SENT Besides_RB ,_, CBP/p300_NP interacts_VBZ with_IN members_NNS of_IN the_DT SRC_NP family_NN and_CC synergizes_NNS with_IN SRC-1_NP in_IN the_DT transactivation_NN of_IN the_DT ER_NN and_CC the_DT PR_NP ._SENT Other_JJ coactivators_NNS |_SYM In_IN addition_NN to_TO the_DT coactivators_NNS already_RB discussed_VBN ,_, there_EX are_VBP a_DT few_JJ other_JJ proteins_NNS that_WDT have_VBP been_VBN demonstrated_VBN to_TO upregulate_VB the_DT transcriptional_JJ activity_NN of_IN the_DT PR_NP ._SENT Chromatin_NN high-mobility_NN group_NN protein_NN 1_CD ,_, chromatin_NN high-mobility_NN group_NN protein_NN 2_CD ,_, TIP60_NP (_( Tat-interacting_NP protein_NN )_) ,_, proline-rich_JJ nuclear_JJ receptor_NN coregulatory_NN protein_NN 1_CD ,_, proline-rich_JJ nuclear_JJ receptor_NN coregulatory_NN protein_NN 2_CD ,_, Cdc25B_NP ,_, and_CC GT198_NP all_DT function_NN as_IN PR_NP coactivators_NNS ,_, as_RB demonstrated_VBN by_IN transient_JJ transfection_NN assays_NNS ._SENT Cdc25B_NP is_VBZ prominent_JJ among_IN these_DT coactivators_NNS in_IN terms_NNS of_IN its_PP$ roles_NNS in_IN breast_NN cancer_NN development_NN ,_, because_IN Cdc25B_NP transgenic_JJ mice_NNS exhibit_VBP mammary_JJ gland_NN hyperplasia_NN and_CC increased_VBN steroid_NN hormone_NN responsiveness_NN ._SENT The_DT significance_NN of_IN all_PDT these_DT coactivators_NNS in_IN vivo_JJ needs_NNS to_TO be_VB further_RBR investigated_VBN ._SENT Nuclear_JJ receptor_NN corepressor/silencing_NN mediator_NN of_IN retinoid_NN and_CC thyroid_JJ receptors_NNS |_SYM Nuclear_JJ receptor_NN corepressor_NN (_( N-CoR_NP )_) and_CC silencing_VBG mediator_NN of_IN retinoid_NN and_CC thyroid_JJ receptor_NN (_( SMRT_NP )_) are_VBP both_DT corepressors_NNS of_IN numerous_JJ transcription_NN factors_NNS ,_, including_VBG steroid_NN hormone_NN receptors_NNS ._SENT Both_DT N-CoR_NP and_CC SMRT_NP interact_VBP with_IN the_DT nuclear_JJ receptors_NNS through_IN the_DT receptor-interacting_NN domains_NNS located_VBN in_IN the_DT C-terminal_JJ portion_NN of_IN the_DT proteins_NNS ,_, while_IN their_PP$ transcriptional_JJ repression_NN domains_NNS are_VBP mapped_VBN to_TO the_DT N-termini_NP ._SENT N-CoR_NP and_CC SMRT_NP also_RB associate_VBP with_IN HDAC3_NP in_IN large_JJ protein_NN complexes_NNS ,_, which_WDT is_VBZ an_DT important_JJ pathway_NN for_IN transcriptional_JJ repression_NN ._SENT Corepressors_NP N-CoR_NP and_CC SMRT_NP interact_VBP with_IN the_DT nuclear_JJ receptors_NNS either_CC in_IN the_DT absence_NN of_IN agonists_NNS (_( in_IN the_DT case_NN of_IN the_DT thyroid_JJ receptor_NN and_CC the_DT retinoid_NN acid_NN receptor_NN )_) or_CC in_IN the_DT presence_NN of_IN antagonists_NNS (_( in_IN the_DT case_NN of_IN steroid_NN receptors_NNS )_) ._SENT Since_IN N-CoR_NP and_CC SMRT_NP are_VBP common_JJ corepressors_NNS for_IN transcription_NN factors_NNS ,_, slight_JJ alteration_NN of_IN their_PP$ expression_NN level_NN in_IN certain_JJ tissues_NNS might_MD result_VB in_IN significant_JJ transcriptional_JJ changes_NNS ,_, leading_VBG to_TO altered_JJ development_NN of_IN the_DT mammary_JJ gland_NN ,_, even_RB tumors_NNS ._SENT BRCA1_NN |_SYM BRCA1_NP is_VBZ a_DT breast_NN cancer_NN susceptibility_NN gene_NN ,_, and_CC its_PP$ inherited_JJ mutations_NNS are_VBP correlated_VBN with_IN an_DT increased_VBN risk_NN of_IN breast_NN cancer_NN and_CC ovarian_JJ cancer_NN ._SENT The_DT role_NN of_IN BRCA1_NP in_IN cancer_NN development_NN is_VBZ unclear_JJ ._SENT In_IN addition_NN to_TO its_PP$ ability_NN to_TO coactivate_JJ p53_NN and_CC to_TO modulate_VB p300/CBP_NN expression_NN ,_, BRCA1_NP is_VBZ also_RB a_DT ligand-independent_JJ corepressor_NN for_IN the_DT ER_NN ,_, the_DT androgen_NN receptor_NN and_CC the_DT PR_NP ._SENT If_IN BRCA1_NP is_VBZ mutated_VBN ,_, all_RB of_IN these_DT pathways_NNS will_MD be_VB more_JJR or_CC less_RBR impaired_JJ ._SENT The_DT effect_NN of_IN BRCA1_NP in_IN cancer_NN development_NN might_MD therefore_RB be_VB multiplex_JJ ._SENT Other_JJ corepressors_NNS |_SYM Ubiquitin-activating_JJ enzyme_NN 3_CD (_( Uba3_NP )_) is_VBZ the_DT catalytic_JJ subunit_NN of_IN the_DT activating_VBG enzyme_NN in_IN the_DT ubiquitin-like_JJ NEDD8_NP (_( neural_JJ precursor_NN cell-expressed_VBD developmentally_RB downregulated_JJ )_) conjugation_NN (_( neddylation_NN )_) pathway_NN ._SENT Uba3_NP was_VBD recently_RB demonstrated_VBN as_IN a_DT corepressor_NN of_IN the_DT ER_NN ,_, the_DT androgen_NN receptor_NN and_CC the_DT PR_NP in_IN mammalian_JJ transfection_NN assays_NNS ._SENT Uba3_NP inhibited_VBD the_DT transactivation_NN of_IN the_DT ER_NN in_IN a_DT time-dependent_JJ manner_NN ,_, and_CC neddylation_NN activity_NN of_IN Uba3_NP is_VBZ required_VBN for_IN this_DT suppression_NN ._SENT This_DT suggests_VBZ that_IN Uba3_NP suppresses_VBZ steroid_NN receptor_NN activity_NN by_IN promoting_VBG the_DT termination_NN of_IN receptor-mediated_JJ gene_NN transcription_NN rather_RB than_IN by_IN interfering_VBG with_IN the_DT initial_JJ events_NNS ._SENT Repressor_NN of_IN tamoxifen_NP transcriptional_JJ activity_NN (_( RTA_NP )_) has_VBZ recently_RB been_VBN defined_VBN as_IN a_DT potent_JJ repressor_NN of_IN tamoxifen-mediated_JJ ERalpha_NP transcriptional_JJ activity_NN as_RB well_RB as_IN an_DT agonist_NN of_IN the_DT ERbeta_NP ,_, the_DT glucocorticoid_JJ receptor_NN ,_, and_CC the_DT PR_NP ._SENT The_DT interaction_NN of_IN RTA_NP with_IN the_DT nuclear_JJ receptors_NNS requires_VBZ the_DT participation_NN of_IN RNA_NP ,_, because_IN mutation_NN of_IN the_DT RNA_NP recognition_NN motif_NN in_IN RTA_NP compromises_VBZ its_PP$ ability_NN to_TO repress_VB transcription_NN ._SENT The_DT roles_NNS of_IN Uba3_NP and_CC RTA_NP in_IN mammary_JJ gland_NN development_NN and_CC tumorigenesis_NN await_VBP further_JJR study_NN ._SENT As_IN a_DT transcription_NN factor_NN ,_, the_DT PR_NP activates_VBZ target_NN gene_NN transcription_NN in_IN response_NN to_TO the_DT hormonal_JJ stimulus_NN ,_, and_CC its_PP$ functions_NNS are_VBP modulated_VBN by_IN coactivators_NNS and_CC corepressors_NNS ._SENT Different_JJ coregulators_NNS exert_VBP their_PP$ actions_NNS through_IN different_JJ mechanisms_NNS ,_, and_CC involvement_NN in_IN the_DT development_NN of_IN normal_JJ mammary_JJ gland_NN and_CC the_DT formation_NN or_CC progression_NN of_IN tumors_NNS has_VBZ been_VBN reported_VBN in_IN some_DT coactivators_NNS and_CC some_DT corepressors_NNS ._SENT The_DT coactivators_NNS and_CC corepressors_NNS of_IN the_DT PR_NP so_RB far_RB identified_VBN are_VBP not_RB PR_NP specific_NN ,_, since_IN they_PP can_MD also_RB modulate_VB the_DT transactivation_NN of_IN many_JJ other_JJ nuclear_JJ receptors_NNS ._SENT In_IN addition_NN ,_, no_DT unique_JJ coregulators_NNS of_IN PR-A_NP or_CC PR-B_NP have_VBP been_VBN identified_VBN ._SENT Identification_NN of_IN PR-specific_JJ coregulatory_JJ proteins_NNS ,_, especially_RB PR-A_NP interacting_VBG factors_NNS or_CC PR-B_NN interacting_VBG factors_NNS ,_, is_VBZ an_DT important_JJ goal_NN of_IN future_JJ study_NN ._SENT AF_NN =_SYM activation_NN function_NN domain_NN ;_: CBP_NP =_SYM CREB-binding_JJ protein_NN ;_: E6-AP_NP =_SYM E6-associated_JJ protein_NN ;_: ER_NP =_SYM estrogen_NN receptor_NN ;_: N-CoR_NP =_SYM nuclear_JJ receptor_NN corepressor_NN ;_: PR_NP =_SYM progesterone_NN receptor_NN ;_: RPF1_NP =_SYM receptor_NN potentiation_NN factor-1_NN ;_: RTA_NP =_SYM repressor_NN of_IN tamoxifen_NP transcriptional_JJ activity_NN ;_: SMRT_NP =_SYM silencing_VBG mediator_NN of_IN retinoid_NN and_CC thyroid_JJ receptor_NN ;_: SRA_NP =_SYM steroid_NN receptor_NN RNA_NP activator_NN ;_: SRC_NP =_SYM steroid_NN receptor_NN coactivator_NN ;_: Uba3_NP =_SYM ubiquitin-activating_JJ enzyme_NN ._SENT 